Welcome to our dedicated page for Predictmedix news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Predictmedix stock.
Predictmedix AI Inc. (PMEDF) is a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI). The company recently announced a partnership with KGK Science, a renowned name in clinical research, to advance health research and product development. This collaboration aims to introduce transformative changes in healthcare innovation, particularly in clinical trial efficiency and health product development. By leveraging Predictmedix AI's cutting-edge technologies and KGK Science's expertise, the partnership is set to redefine health assessment methodologies and outcomes.
KGK Science, with over 22 years of experience, is known for its expertise in clinical research and regulatory support for nutraceutical, cannabis, and hemp industries. On the other hand, Predictmedix AI's Safe Entry Stations utilize multispectral cameras to predict a variety of health issues, including vital parameters, drug impairment, fatigue, and mental illnesses. Together, these companies are focused on enhancing health research and product development through innovative technologies and creating impactful advancements in healthcare solutions.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has successfully closed the first tranche of its non-brokered private placement, raising $320,000 through the issuance of 16,000,000 units at $0.02 per unit. Each unit comprises one common share and one purchase warrant, exercisable at $0.05 per share for 24 months.
The warrant expiry date may be accelerated if the company's shares trade at $0.10 or higher for ten consecutive trading days on the CSE, with a minimum 30-day notice to holders. The proceeds will be used to expand U.S. market opportunities for Predictmedix's AI-driven health management solutions in enterprise and government sectors.
Additionally, the company granted 2,000,000 stock options to a consultant, exercisable at $0.05 per share with a one-year term. All securities issued are subject to a four-month and one-day statutory hold period.
Predictmedix AI (PMEDF) announced a strategic repositioning, shifting its focus from traditional healthcare to AI-powered health management technologies. The company is developing solutions for workplace safety, workforce readiness, and public sector health screening.
The company's AI-driven solutions aim to help businesses assess workforce readiness through detection of fatigue, vital signs monitoring, and substance impairment screening. These technologies are designed to integrate with HR, compliance, and safety protocols in industries such as manufacturing, logistics, energy, construction, and defense.
Additionally, Predictmedix AI is exploring opportunities in defense, public safety, and education sectors, focusing on workplace health monitoring applications and AI-driven assessments for law enforcement and military personnel.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has announced a non-brokered private placement offering of up to 50,000,000 units at C$0.02 per unit, aiming to raise up to C$1,000,000. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of one common share at C$0.05 within 24 months of closing.
The company has begun receiving commitments for the placement, according to COO Dr. Rahul Kushwah. The proceeds will be allocated to general working capital and expanding market opportunities in the U.S. for AI-powered health management solutions across enterprise and government sectors. All securities issued will have a four-month and one-day statutory hold period.
FAQ
What is the current stock price of Predictmedix (PMEDF)?
What is the market cap of Predictmedix (PMEDF)?
What is Predictmedix AI Inc. known for?
Who is KGK Science and what expertise do they bring to the partnership?
What are the key focus areas of the partnership between Predictmedix AI Inc. and KGK Science?
How do Predictmedix AI's Safe Entry Stations contribute to the partnership?
What are the expected outcomes of the collaboration between Predictmedix AI Inc. and KGK Science?
